LUMAKRAS® SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL Market News
Opdivo® in Combination with CABOMETYX® Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Pharmaceutical Investing
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® in Pediatric Patients With COVID-19 Presented at CROI 2022 Pharmaceutical Investing
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults Pharmaceutical Investing
Veklury® Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies Pharmaceutical Investing
BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update Life Science Investing
